Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Michael_A._Sherman
|
| gptkbp:collaboratesWith |
Biomedical Advanced Research and Development Authority (BARDA)
|
| gptkbp:focus |
antiviral therapeutics
|
| gptkbp:foundedYear |
2000
|
| gptkbp:founder |
gptkb:George_Painter
|
| gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Russell_2000_Index
|
| gptkbp:notableEvent |
brincidofovir approved for smallpox treatment by FDA in 2021
|
| gptkbp:notableProduct |
gptkb:brincidofovir
ONC201 |
| gptkbp:numberOfEmployees |
approximately 60 (2023)
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
infectious diseases
oncology |
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CMRX
|
| gptkbp:website |
https://www.chimerix.com/
|
| gptkbp:bfsParent |
gptkb:Chimerix
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chimerix, Inc.
|